REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
15.02
+0.92 (6.52%)
At close: Jan 21, 2026, 4:00 PM EST
15.15
+0.13 (0.87%)
After-hours: Jan 21, 2026, 7:53 PM EST
REGENXBIO Employees
REGENXBIO had 353 employees as of December 31, 2024. The number of employees increased by 9 or 2.62% compared to the previous year.
Employees
353
Change (1Y)
9
Growth (1Y)
2.62%
Revenue / Employee
$456,992
Profits / Employee
-$504,008
Market Cap
760.36M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 353 | 9 | 2.62% |
| Dec 31, 2023 | 344 | -57 | -14.21% |
| Dec 31, 2022 | 401 | 29 | 7.80% |
| Dec 31, 2021 | 372 | 66 | 21.57% |
| Dec 31, 2020 | 306 | 49 | 19.07% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 579 |
| Prime Medicine | 214 |
| Kura Oncology | 192 |
| Vor Biopharma | 159 |
| Astria Therapeutics | 78 |
| Nektar Therapeutics | 61 |
| Fulcrum Therapeutics | 45 |
| Jade Biosciences | 30 |
RGNX News
- 7 days ago - REGENXBIO Inc. (RGNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program - PRNewsWire
- 4 weeks ago - REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - REGENXBIO to Participate in Upcoming Investor Conference - PRNewsWire
- 2 months ago - REGENXBIO Inc. (RGNX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights - PRNewsWire
- 2 months ago - REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program - PRNewsWire
- 3 months ago - REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights - PRNewsWire